BioSense 2.0 uses predetermined syndromes based upon ICD-9 codes and chief complaint data to allow users to view and analyze data from emergency department (ED) visits, yet further validations of these syndromes are needed. Previous studies have validated syndromic surveillance syndromes by comparing chief complaint data to discharge diagnosis; however, these efforts are not possible for jurisdictions in which facilities do not submit ICD-9 code data. Currently in Utah, the syndromic surveillance data submitted includes only chief complaint information.

The May arrival of two cases of Middle East Respiratory Syndrome (MERS) in the US offered CDC’s BioSense SyS Program an opportunity to give CDC’s Emergency Operations Center (EOC) and state-and-local jurisdictions an enhanced national picture of MERS surveillance. BioSense jurisdictions can directly query raw data stored in what is known as “the locker.” However, CDC cannot access these data and critical functions, like creating ad-hoc syndrome definitions within the application are currently not possible. These were obstacles to providing the EOC with MERS information.

BioSense 2.0, a redesigned national syndromic surveillance system, provides users with timely regional and national data classified into disease syndromes, with views of health outcomes and trends for use in situational awareness. As of July 2014, there are 60 jurisdictions nationwide feeding data into BioSense 2.0. In New Jersey, the state’s syndromic surveillance system, EpiCenter, receives registration data from 75 of NJ’s 80 acute care and satellite emergency departments. EpiCenter is a system developed by Health Monitoring Systems, Inc.